Print

ANDA Litigation Settlements

Case Name Drug Patent No(s). Publicly Available Terms
Kissei Pharm. Co. Ltd. v. Sandoz Inc., 13-1092 (D. Del.) Rapaflo® (silodosin capsules) 5,387,603 N/A
Shire LLC v. Amerigen Pharms. Ltd., 14-6095 (D.N.J.) Adderall® XR (amphetamine / dextroamphetamine) RE41,148 RE42,096 Defendant acknowledges that patents-in-suit are valid and enforceable; that selling a generic version of Adderall XR would infringe those patents; and until patent expiration, Defendant can only sell a generic product with Plaintiff’s permission.
PDL BioPharma Inc. v. Merck Sharp & Dohme Corp., 16-0407 (D.N.J.) Keytruda® (pembrolizumab for injection) 5,693,761 Merck will pay $19.5 million to license related patent rights and dismiss the case; and PDL agreed to not sue Merck for royalties related to Keytruda in the future.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.